Kateryna V. Vilchevska
Ukraine
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Efficacy and Safety of Prophylaxis With a Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease-A WIL-31 Study Sub-Analysis.
Journal: European journal of haematology
Published: August 18, 2025
Efficacy and safety of plasma-derived von Willebrand factor/factor VIII concentrate (wilate) prophylaxis in children and adolescents with von Willebrand disease - WIL-31 study post hoc analysis.
Journal: Research and practice in thrombosis and haemostasis
Published: January 06, 2025
Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials.
Journal: Blood vessels, thrombosis & hemostasis
Published: December 24, 2024
Efficacy of Wilate Prophylaxis in Reducing Nosebleeds in Patients with Severe VWD - A Post-hoc Analysis of the WIL-31 Study.
Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: December 18, 2024
Trenonacog alfa safety, efficacy, and pharmacokinetics in previously treated pediatric hemophilia B.
Trenonacog alfa safety, efficacy, and pharmacokinetics in previously treated pediatric hemophilia B.
Journal: Research and practice in thrombosis and haemostasis
Published: June 18, 2024
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
Journal: The New England journal of medicine
Published: August 30, 2023
Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
Journal: European journal of haematology
Published: March 17, 2023
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: January 04, 2022
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: May 14, 2021
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: April 13, 2021
Last Updated: 09/26/2026